Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Receptor antibodies as novel therapeutics for diabetes.

Literature DB >> 22174312

Receptor antibodies as novel therapeutics for diabetes.

Siegfried Ussar¹, Sara G Vienberg, C Ronald Kahn.

Abstract

Antibodies to receptors can block or mimic hormone action. Taking advantage of receptor isoforms, co-receptors, and other receptor modulating proteins, antibodies and other designer ligands can enhance tissue specificity and provide new approaches to the therapy of diabetes and other diseases.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 22174312 PMCID： PMC4374142 DOI： 10.1126/scitranslmed.3003447

Source DB: PubMed Journal: Sci Transl Med ISSN： 1946-6234 Impact factor: 17.956

13 in total

Review 1. Cell-surface co-receptors: emerging roles in signaling and human disease.

Authors: Kellye C Kirkbride; Bridgette N Ray; Gerard C Blobe
Journal: Trends Biochem Sci Date: 2005-09-26 Impact factor: 13.807

2. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.

Authors: Hiroshi Kurosu; Mihwa Choi; Yasushi Ogawa; Addie S Dickson; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Kevin P Rosenblatt; Steven A Kliewer; Makoto Kuro-o
Journal: J Biol Chem Date: 2007-07-10 Impact factor: 5.157

Review 3. FGF21: a novel prospect for the treatment of metabolic diseases.

Authors: Alexei Kharitonenkov; Armen B Shanafelt
Journal: Curr Opin Investig Drugs Date: 2009-04

Review 4. Receptors, antireceptor antibodies and mechanisms of insulin resistance.

Authors: J S Flier; C R Kahn; J Roth
Journal: N Engl J Med Date: 1979-02-22 Impact factor: 91.245

5. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.

Authors: Ai-Luen Wu; Ganesh Kolumam; Scott Stawicki; Yongmei Chen; Jun Li; Jose Zavala-Solorio; Khanhky Phamluong; Bo Feng; Li Li; Scot Marsters; Lance Kates; Nicholas van Bruggen; Maya Leabman; Anne Wong; David West; Howard Stern; Elizabeth Luis; Hok Seon Kim; Daniel Yansura; Andrew S Peterson; Ellen Filvaroff; Yan Wu; Junichiro Sonoda
Journal: Sci Transl Med Date: 2011-12-14 Impact factor: 17.956

6. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats.

Authors: David A Sarruf; Joshua P Thaler; Gregory J Morton; Jonathan German; Jonathan D Fischer; Kayoko Ogimoto; Michael W Schwartz
Journal: Diabetes Date: 2010-03-31 Impact factor: 9.461

7. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state.

Authors: Ffolliott M Fisher; Patricia C Chui; Patrick J Antonellis; Holly A Bina; Alexei Kharitonenkov; Jeffrey S Flier; Eleftheria Maratos-Flier
Journal: Diabetes Date: 2010-08-03 Impact factor: 9.461

8. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis.

Authors: Emily A Partridge; Christine Le Roy; Gianni M Di Guglielmo; Judy Pawling; Pam Cheung; Maria Granovsky; Ivan R Nabi; Jeffrey L Wrana; James W Dennis
Journal: Science Date: 2004-10-01 Impact factor: 47.728

Review 9. Autoimmune disorders of the neuromuscular junction.

Authors: Bethan Lang; Angela Vincent
Journal: Curr Opin Pharmacol Date: 2009-05-08 Impact factor: 5.547

Review 10. TSH receptor autoantibodies.

Authors: Krzysztof Michalek; Syed A Morshed; Rauf Latif; Terry F Davies
Journal: Autoimmun Rev Date: 2009-03-27 Impact factor: 9.754

6 in total

Review 1. The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes.

Authors: Maitane Izaguirre; María J Gil; Ignacio Monreal; Fabrizio Montecucco; Gema Frühbeck; Victoria Catalán
Journal: Curr Diab Rep Date: 2017-06 Impact factor: 4.810

2. Epitope-specificity of recombinant antibodies reveals promiscuous peptide-binding properties.

Authors: Niclas Olsson; Stefan Wallin; Peter James; Carl A K Borrebaeck; Christer Wingren
Journal: Protein Sci Date: 2012-10-25 Impact factor: 6.725

3. Selective allosteric antibodies to the insulin receptor for the treatment of hyperglycemic and hypoglycemic disorders.

Authors: Hassan Issafras; Daniel H Bedinger; John A Corbin; Ira D Goldfine; Vinay Bhaskar; Mark L White; Paul Rubin; Patrick J Scannon
Journal: J Diabetes Sci Technol Date: 2014-04-07

Review 4. Theoretical and computational studies of peptides and receptors of the insulin family.

Authors: Harish Vashisth
Journal: Membranes (Basel) Date: 2015-02-11

5. Improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinity.

Authors: John A Corbin; Vinay Bhaskar; Ira D Goldfine; Daniel H Bedinger; Angela Lau; Kristen Michelson; Lisa M Gross; Betty A Maddux; Hua F Kuan; Catarina Tran; Llewelyn Lao; Masahisa Handa; Susan R Watson; Ajay J Narasimha; Shirley Zhu; Raphael Levy; Lynn Webster; Sujeewa D Wijesuriya; Naichi Liu; Xiaorong Wu; David Chemla-Vogel; Steve R Lee; Steve Wong; Diane Wilcock; Mark L White
Journal: PLoS One Date: 2014-02-12 Impact factor: 3.240

6. Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: a potential new approach for the treatment of hyperinsulinemic hypoglycemia.

Authors: John A Corbin; Vinay Bhaskar; Ira D Goldfine; Hassan Issafras; Daniel H Bedinger; Angela Lau; Kristen Michelson; Lisa M Gross; Betty A Maddux; Hua F Kuan; Catarina Tran; Llewelyn Lao; Masahisa Handa; Susan R Watson; Ajay J Narasimha; Shirley Zhu; Raphael Levy; Lynn Webster; Sujeewa D Wijesuriya; Naichi Liu; Xiaorong Wu; David Chemla-Vogel; Steve R Lee; Steve Wong; Diane Wilcock; Paul Rubin; Mark L White
Journal: MAbs Date: 2014 Jan-Feb Impact factor: 5.857

6 in total